Psychedelic Therapy: Uses, How It’s Done, Risks, and More

What Is Psychedelic Therapy?

Psychedelic therapy (sometimes called psychedelic-assisted psychotherapy, or PAP) involves using a psychedelic substance as part of a structured therapeutic process, typically under the supervision of a trained clinician or guide. The substance itself is not the treatment in isolation. It is used to support and deepen the therapeutic work happening before, during, and after the experience.

Several substances fall under this umbrella. Some are plant-derived: psilocybin (from magic mushrooms), DMT, peyote, ayahuasca, and ibogaine. Others are synthetic compounds, including ketamine, MDMA, and LSD. Indigenous communities have used many of these substances in healing and ceremonial contexts for centuries. Their use in Western clinical settings, however, is relatively recent, with serious scientific research picking up in the last few decades after a long pause following the Controlled Substances Act of 1970.

Today, renewed funding and a growing mental health crisis have brought psychedelic therapy back into serious research focus. The results so far are cautiously encouraging.

What Conditions Is It Being Studied For?

Before the 1970s research ban, scientists had already begun accumulating meaningful evidence on the therapeutic potential of psychedelics. Current research is building on that foundation, and several areas are now well into clinical trials.

Ketamine

Ketamine is currently the most studied and most widely available psychedelic medicine in clinical settings. In controlled doses, it has shown meaningful improvement in people with treatment-resistant depression, with effects typically lasting around six to eight weeks. This research directly contributed to the development of esketamine (marketed as Spravato), an FDA-approved nasal spray. Intravenous ketamine infusions are also in use, and many clinicians consider them more effective, though access varies considerably by location.

MDMA

MDMA-assisted therapy for PTSD has produced some of the most striking results in the field. Phase 2 trials showed sustained symptom reduction lasting up to four years in some participants. In a Phase 3 trial involving 90 people with severe PTSD, 67 percent no longer met the diagnostic criteria for PTSD after three treatment sessions, and 88 percent showed measurable reduction in symptoms. The FDA ultimately declined to approve MDMA-assisted therapy in 2024, citing the need for additional data, but research continues and the clinical interest remains strong.

Psilocybin

Psilocybin, the active compound in magic mushrooms, has shown real promise for depression and anxiety in people with terminal illness diagnoses, as well as for treatment-resistant depression more broadly. Researchers are also investigating its potential for obsessive-compulsive disorder and substance use disorders. The data is early in several of these areas, and more trials are underway. What makes psilocybin particularly interesting to researchers is the apparent durability of its effects, often after just one or two sessions.

LSD

LSD, one of the most potent and longest-acting psychedelics, was the focus of much of the early research in the 1950s and 60s. Modern studies are revisiting its potential for alcohol use disorder and end-of-life anxiety, with early findings that echo what researchers observed decades ago. Its long duration of action (often 8 to 12 hours) creates practical challenges for clinical use, but interest in its therapeutic properties has not faded.

How Psychedelic Therapy Is Structured

While protocols vary depending on the substance, the setting, and the provider, most clinical models of psychedelic therapy share a common three-phase structure.

Preparation

Before any substance is administered, there is typically one or more preparatory sessions. This phase serves a practical and relational function: screening for contraindications, reviewing personal history, establishing trust with the guide or therapist, and setting intentions for the experience. This is not a formality. The quality of the preparation often shapes the quality of the experience itself.

The Session

The substance is administered under direct supervision, either orally or by injection, depending on the protocol. The number of sessions varies. MDMA-assisted therapy typically involves at least three. Ketamine-assisted therapy can range from one to twelve sessions. Psilocybin and LSD protocols generally involve one to two sessions. Throughout the experience, the therapist or guide is present to provide support without directing the content of the experience.

Integration

Integration is the phase that happens after the experience, and many practitioners consider it the most important part of the process. This is when the client and therapist work together to make sense of what came up, identify patterns, and apply insights to daily life. Without structured integration, the benefits of a psychedelic experience are less likely to hold. This is a core reason why professional support matters so much in this work.

What Are the Risks?

Psychedelic therapy has a real risk profile, and anyone considering it deserves a clear picture of what those risks are.

On a physiological level, MDMA can temporarily raise blood pressure, heart rate, and body temperature, though these effects generally resolve after the session. Psilocybin may cause a short-term increase in blood pressure or mild headaches. These are manageable in a properly supervised setting.

The more serious concerns involve mental health history. Psychedelics have been linked to an elevated risk of psychosis in individuals with psychotic disorders or a genetic predisposition to them. Anyone with a personal or family history of schizophrenia or bipolar disorder with psychotic features should approach this territory with significant caution and professional guidance. LSD use, particularly without supervision, has also been associated with hallucinogen persisting perception disorder (HPPD), a rare but real condition involving persistent flashbacks and visual disturbances.

Ibogaine, used primarily in opioid addiction treatment, carries a specific cardiac risk and has been linked to potentially fatal arrhythmias. For this reason, it remains largely confined to observational research and specialized clinical settings.

There is also the risk that comes from the current commercial boom. As interest in psychedelic therapy grows, so does the number of therapists, guides, retreat centers, and clinics entering the space. Not all of them are equally qualified, ethical, or safe. Research settings have documented cases of boundary violations and misconduct. Due diligence matters here, including checking credentials, reading reviews, and understanding how accountability works within any given program.

Self-medicating outside of any professional framework carries its own risks, including unverified substance purity, the absence of screening for contraindications, and no support structure if something goes wrong. These are not abstract concerns.

Why Professional Support Changes the Picture

The evidence consistently points in one direction: outcomes are better, and risks are lower, when psychedelic experiences happen within a structured, professionally supported framework. That framework includes preparation, a vetted and trained guide present during the session, and a clear integration process afterward.

This is what JourneyOM is built around. We are not a marketplace or a retreat booking service. We match seekers with vetted professional guides and support continuity of care across the full arc of the experience, from initial readiness assessment through post-journey integration. Our role is to be the safety and quality layer that makes this work as it should.

Psychedelic therapy is evolving fast. The research is genuinely promising, and the potential for people who have not responded to conventional treatments is real. But the quality of the support around the experience matters as much as the experience itself.